Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

43). Table 3 (page 2741)should have included a footnote for Grade 4 adverse events: "A total of 13 grade 4 adverse events occurred among 10 (6%) of the patients receiving lapatinib plus capecitabine, and 16 grade 4 adverse events occurred among 11 (7%) of the patients receiving capecitabine alone.These differences are not significant."The table has been corrected on the Journal's Web site at www.nejm.org.Synergistic Copathogens -HIV-1 and HSV-2 (February 22, 2007;356:854-6).The fourth sentence of the fourth paragraph (page 855) should have read "As Nagot et al. show with sampling every 2 weeks, 50% of patients who are coinfected with HSV-2 and HIV-1 shed HSV-2 virus asymptomatically" rather than "with once-weekly sampling."The text has been corrected on the Journal's Web site at www.nejm.org.